Clinical trial
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With…
NCT00074919 · Genzyme, a Sanofi Company, Industry · Approved for marketing
Key facts
| NCT number | NCT00074919 |
|---|---|
| Title | Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease |
| Official title | Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Glycogen Storage Disease Type II, Glycogenosis 2 |
| Intervention type | Biological |
| Interventions | alglucosidase alfa |
| Start date | Dec 1, 2003 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 25, 2003 |
| Last update posted | Feb 5, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: